发明名称 |
PEPTIDES FOR USE IN THE TOPICAL TREATMENT OF RETINAL NEURODEGENERATIVE DISESASES, IN PARTICULAR IN EARLY STAGES OF DIABETIC RETINOPATHY AND OTHER RETINAL DISEASES IN WHICH NEURODEGENERATION PLAYS AN ESSENTIAL ROLE |
摘要 |
The invention relates to peptides with a sequence length from 13 to 50 amino acids, the N-terminal region of said peptides consisting in the sequence HXaa1EGTFTSDXaa2SXaa3Xaa4 (SEQ ID NO: 1) wherein: Xaa1 is an amino acid selected from alanine and glycine; Xaa2 is an amino acid selected from valine and leucine; Xaa3 is an amino acid selected from serine and lysine; Xaa4 is an amino acid selected from tyrosine and glutamine; and Hystidine is the N-terminal residue; for use in the topical treatment and/or prevention of retinal neurodegenerative diseases, in particular diabetic retinopathy. The invention also encompasses pharmaceutical topical compositions for use in the topical treatment and/or prevention of these diseases. |
申请公布号 |
US2016000882(A1) |
申请公布日期 |
2016.01.07 |
申请号 |
US201414770067 |
申请日期 |
2014.02.27 |
申请人 |
FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA |
发明人 |
SIMÓ CANONGE Rafael;HERNÁNDEZ PASCUAL Cristina |
分类号 |
A61K38/26;A61K9/00;A61K38/10 |
主分类号 |
A61K38/26 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method for the treatment and/or prevention of a retinal neurodegenerative disease comprising topically administering in the eye a therapeutically effective amount of a peptide, which is able to reach the retina, with a sequence length from 13 to 50 amino acids, the N-terminal region of said peptide having the sequence:
HXaa1EGTFTSDXaa2SXaa3Xaa4 (SEQ ID NO: 1) wherein:
Xaa1 is an amino acid selected from alanine and glycine;Xaa2 is an amino acid selected from valine and leucine;Xaa3 is an amino acid selected from serine and lysine;Xaa4 is an amino acid selected from tyrosine and glutamine; andhystidine is the N-terminal residue;together with pharmaceutically acceptable excipients and/or carriers, in a subject in need thereof, including a human. |
地址 |
Barcelona ES |